ATRA
Atara Biotherapeutics, Inc.
There isn't enough reported data to score ATRA yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
ATRA Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Under pressure | |
| Strong |
ATRA's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ATRA PE Valuation
ATRA has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
ATRA Forward outlook
There aren't enough analyst estimates for ATRA to show an outlook.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
ATRA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$25.53 | +$44.22 |
| Q2 2024 | -$39.10 | +$34.65 |
| Q1 2024 | -$53.00 | -$0.75 |
| Q4 2023 | -$65.25 | -$9.25 |
| Q3 2023 | -$69.75 | -$8.00 |
| Q2 2023 | -$73.75 | -$10.00 |
| Q1 2023 | -$52.25 | +$38.75 |
| Q4 2022 | -$56.00 | +$34.75 |
OSCR has the stronger earnings trend. Trailing diluted EPS is down 106% for ATRA versus OSCR up 147%.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
ATRA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.2M | -65% |
| Q2 2026 | $630K | -96% |
| Q1 2026 | $516K | -99% |
| Q4 2025 | $1.6M | -95% |
| Q3 2025 | $3.5M | -91% |
| Q2 2025 | $17.6M | -39% |
| Q1 2025 | $98.1M | +259% |
| Q4 2024 | $32.8M | +670% |
ATRA's revenue has slid since its 2025 peak: $1M last quarter, down 65% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -243% | -139 points |
| Q2 2026 | -749% | -767 points |
| Q1 2026 | -653% | -692 points |
| Q4 2025 | -161% | -123 points |
| Q3 2025 | -104% | -49 points |
| Q2 2025 | 18% | +82 points |
| Q1 2025 | 40% | +154 points |
| Q4 2024 | -37% | +1373 points |
ATRA's operating margin was −243% last quarter, down 139 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over ATRA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over ATRA on profitability, with a higher operating margin.
ATRA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$879K | +$8.9M |
| Q2 2026 | -$3.3M | +$4M |
| Q1 2026 | -$3.1M | +$25.1M |
| Q4 2025 | -$5.7M | +$18.9M |
| Q3 2025 | -$9.8M | -$5.8M |
| Q2 2025 | -$7.3M | +$3.4M |
| Q1 2025 | -$28.1M | +$1.6M |
| Q4 2024 | -$24.6M | +$25.9M |
ATRA has burned cash in almost every quarter: −$13M over the past year, against −$70M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over ATRA on cash generation, producing positive trailing cash flow while its opponent burns cash.
ATRA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.9% | +293K shares |
| 1 year | +25% | +3M shares |
| 3 years | +269% | +11.2M shares |
| 5 years | +319% | +11.7M shares |
| Available history | +647% | +13.3M shares |
ATRA has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ATRA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | -0.2x | Net Cash |
| Q3 2025 | -0.2x | Net Cash |
| Q2 2025 | -1.4x | Net Cash |
ATRA has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
ATRA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.3 | Neutral |
| Stochastic | 12.7 | Oversold |
ATRA's weekly RSI is 44 (neutral) and its Stochastic is 13 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ATRA PE vs Healthcare Sector
ATRA has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
ATRA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.67 | 8.5% below |
| 20 week MA | $8.98 | 12% below |
| 50 week MA | $8.74 | 9.3% below |
| 100 week MA | $9.48 | 16% below |
| 200 week MA | $21.2 | 63% below |
ATRA is in a downtrend: it's below all five of its weekly moving averages, and 63% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over ATRA on trend strength, trading above more of its moving averages.
ATRA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $412.8 | $554.5 | +34% |
| 2021 | $554.5 | $432.8 | -22% |
| 2022 | $432.8 | $74.8 | -83% |
| 2023 | $74.8 | $12.8 | -83% |
| 2024 | $12.8 | $12.2 | -5.2% |
| 2025 | $12.2 | $17.3 | +42% |
| 2026 YTD | $17.3 | $7.93 | -54% |
ATRA has finished lower in four of the last six years. It's down 54% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over ATRA on returns for 2026, with the stronger performance.